Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation

[1]  M. Sorror,et al.  Pre-Transplant Expressions of Micrornas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT) , 2015 .

[2]  Sonali M. Smith,et al.  Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  M. Sorror,et al.  Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation , 2015, British journal of haematology.

[4]  M. Sorror,et al.  Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Sorror,et al.  Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  M. Sorror,et al.  Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  H. Atkins,et al.  Blood and marrow transplant clinical trials network state of the Science Symposium 2014. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  J. Szer,et al.  Validating the Allogeneic Stem Cell Transplantation Disease Risk Index: Sample Size, Follow-up, and Local Data Are Important , 2015, Transplantation.

[9]  F. Santolaria,et al.  Prognostic value of physical function tests: hand grip strength and six-minute walking test in elderly hospitalized patients , 2014, Scientific Reports.

[10]  M. Sorror,et al.  Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts , 2014 .

[11]  J. Scandura,et al.  Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) , 2014 .

[12]  E. Estey,et al.  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. , 2014, Hematology. American Society of Hematology. Education Program.

[13]  E. Estey,et al.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Y. Kanda,et al.  Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  M. Sorror,et al.  "To combine or not to combine": optimizing risk assessment before allogeneic hematopoietic cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  C. Dantin,et al.  Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  R. Larson,et al.  Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients , 2014, Haematologica.

[18]  H. Deeg,et al.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. , 2014, Blood.

[19]  M. Horowitz,et al.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.

[20]  L. Xu,et al.  EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation , 2014, Bone Marrow Transplantation.

[21]  S. Theurich,et al.  Pretransplant Comorbidities Maintain Their Impact on Allogeneic Stem Cell Transplantation Outcome 5 Years Posttransplant: A Retrospective Study in a Single German Institution , 2014, ISRN hematology.

[22]  R. Porcher,et al.  Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors , 2014, Haematologica.

[23]  First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: significant impact on different outcomes. , 2013, Experimental hematology.

[24]  L. Daudt,et al.  Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation , 2013, Bone marrow research.

[25]  E. Shpall,et al.  Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Barrett,et al.  Comorbidity Measures In Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (HCT) , 2013 .

[27]  J. Goldberg,et al.  The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) Predicts Outcomes After T Cell Depleted (TCD) Allogeneic HCT For AML and MDS , 2013 .

[28]  J. Liesveld,et al.  The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. , 2013, Leukemia research.

[29]  J. Pidala,et al.  Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  Yu-Hong Chen,et al.  The hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) is an outcome predictor for partially matched related donor transplantation , 2013, American journal of hematology.

[31]  R. Porcher,et al.  Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS , 2013, Bone Marrow Transplantation.

[32]  M. Sorror.  How I assess comorbidities before hematopoietic cell transplantation. , 2013, Blood.

[33]  M. Sorror,et al.  Association of Pre-Transplant Comorbidities with Long-Term Quality of Life (QOL) Among Survivors After Allogeneic Hematopoietic Cell Transplantation (HCT) , 2013 .

[34]  S. Paczesny.  Discovery and validation of graft-versus-host disease biomarkers. , 2011, Blood.

[35]  A. Nagler,et al.  Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity , 2012, Bone Marrow Transplantation.

[36]  R. Fanin,et al.  Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. , 2012, Blood.

[37]  K. Akashi,et al.  Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians , 2012, Bone Marrow Transplantation.

[38]  H. Deeg,et al.  A disease risk index for patients undergoing allogeneic stem cell transplantation. , 2012, Blood.

[39]  M. Horowitz,et al.  MHC-Resident Variation Affects Risks After Unrelated Donor Hematopoietic Cell Transplantation , 2012, Science Translational Medicine.

[40]  A. Gratwohl.  The EBMT risk score , 2012, Bone Marrow Transplantation.

[41]  R. Cohn,et al.  Immunohistochemistry of affected tissue may guide cGVHD treatment decisions , 2012, Bone Marrow Transplantation.

[42]  C. Craddock,et al.  Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation , 2012, Bone Marrow Transplantation.

[43]  K. Rezvani,et al.  EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  Alan M. Miller,et al.  Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  G. Ehninger,et al.  The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  P. Hari,et al.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. , 2011, JAMA.

[47]  R. Willemze,et al.  Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia , 2011, Leukemia.

[48]  L. Möllgård,et al.  Hematopoietic stem cell transplantation rates and long‐term survival in acute myeloid and lymphoblastic leukemia , 2011, Cancer.

[49]  T. Luft,et al.  Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. , 2011, Blood.

[50]  R. Bouabdallah,et al.  Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT , 2011, Bone Marrow Transplantation.

[51]  R. Krance,et al.  Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. , 2011, Blood.

[52]  M. Sorror,et al.  Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights , 2011, Bone Marrow Transplantation.

[53]  M. Horowitz,et al.  Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Studenski,et al.  Gait speed and survival in older adults. , 2011, JAMA.

[55]  M. Caligiuri,et al.  Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Katayoun Rezvani,et al.  Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. , 2010, Blood.

[57]  C. Le,et al.  A modified comorbidity index for hematopoietic cell transplantation , 2010, Bone Marrow Transplantation.

[58]  B. Dörken,et al.  A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia , 2010, Haematologica.

[59]  G. Mufti,et al.  Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML , 2010, Bone Marrow Transplantation.

[60]  J. Briones,et al.  Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[61]  M. Kurokawa,et al.  Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study , 2010, Bone Marrow Transplantation.

[62]  H. Deeg,et al.  Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes , 2009, Bone Marrow Transplantation.

[63]  B. Andersson,et al.  Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. , 2009 .

[64]  R. Brand,et al.  Risk score for outcome after allogeneic hematopoietic stem cell transplantation , 2009, Cancer.

[65]  R. Fanin,et al.  The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation , 2009, Leukemia.

[66]  C. Bredeson,et al.  Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center , 2009, Bone Marrow Transplantation.

[67]  R. Larson,et al.  Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[68]  L. Zhao,et al.  Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. , 2008, The New England journal of medicine.

[69]  J. Radich,et al.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  C. Le,et al.  Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[71]  R. Porcher,et al.  Impact of comorbidity indexes on non-relapse mortality , 2008, Leukemia.

[72]  P. Mclaughlin,et al.  Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. , 2008, Blood.

[73]  M. Sorror,et al.  Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.

[74]  A. LaCasce,et al.  Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[75]  M. Sorror,et al.  Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. , 2008, Blood.

[76]  M. Sorror,et al.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.

[77]  F. Appelbaum,et al.  Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[78]  G. Morgan,et al.  Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma , 2007, Haematologica.

[79]  H. Deeg,et al.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  S. Yamasaki,et al.  Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[81]  F. M. Stewart,et al.  Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[82]  J. Gribben,et al.  Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[83]  Erik Andries,et al.  Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. , 2006, Blood.

[84]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[85]  D. Au,et al.  A Risk Score for Mortality after Allogeneic Hematopoietic Cell Transplantation , 2006, Annals of Internal Medicine.

[86]  H. Cohen,et al.  Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). , 2005, Critical reviews in oncology/hematology.

[87]  H. Deeg,et al.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[88]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[89]  Daniel Tabak,et al.  Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome. , 2005, Haematologica.

[90]  John P Klein,et al.  Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants , 2004, British journal of haematology.

[91]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[92]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[93]  J. Hermans,et al.  Bone marrow transplantation for acute nonlymphoblastic leukaemia: a survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.) , 1984, British journal of haematology.